Novartis announced that it will invest in a new radiopharmaceutical manufacturing facility in China to accelerate the introduction of innovative radioligand therapies.
The production base will be located in
the Nuclear Technology Application (Isotope) Industrial Park in Haiyan County,
Zhejiang Province, with a total investment of more than 6 million Yuan. The
site to be built to the highest quality standards for safe and efficient
operations, is expected to be in production by the end of 2026, subject to
regulatory approvals.
To read more please visit:
Source:
Novartis